Catherine Moukheibir - 17 Jun 2026 Form 4 Insider Report for MoonLake Immunotherapeutics (MLTX)

Reporting relationship: Director
Issuer ticker: MLTX
Reported as of: 17 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Jun 2026, 18:45:04 UTC
Prior SEC filing: 17 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Matthias Bodenstedt, Attorney-in-fact for Catherine Moukheibir

Key filing fact

Catherine Moukheibir filed Form 4 for MoonLake Immunotherapeutics (MLTX) on 18 Jun 2026.

Key facts

This page summarizes Catherine Moukheibir's Form 4 filing for MoonLake Immunotherapeutics (MLTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 18 Jun 2026, 18:45.

Change

Previous filing in this sequence was filed on 17 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001772130 Primary reporting owner

Moukheibir Catherine

Relationship: Director
Address: C/O MOONLAKE IMMUNOTHERAPEUTICS, DORFSTRASSE 29, ZUG, SWITZERLAND
Signature: /s/ Matthias Bodenstedt, Attorney-in-fact for Catherine Moukheibir
Signature date: 18 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MLTX transaction Derivative

Option to Buy

Award

Transaction value
Shares: +22,195
Change %
Price: $0.000000^*
Shares after: 22,195
Date: 17 Jun 2026
Ownership: Direct
Underlying class: Class A ordinary shares, par value $0.0001 per share
Underlying amount: 22,195
Exercise price: $19.19
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option represents a right to purchase a total of 22,195 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer.